LE, B., AJ, O., S, A., IS, L., C, D., M, K., . . . JC, C. (2024). Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: A phase 1b/2 trial. Nature medicine, 30(1), 229. https://doi.org/10.1038/s41591-023-02726-5
Chicago Style (17th ed.) CitationLE, Budde, et al. "Mosunetuzumab with Polatuzumab Vedotin in Relapsed or Refractory Aggressive Large B Cell Lymphoma: A Phase 1b/2 Trial." Nature Medicine 30, no. 1 (2024): 229. https://doi.org/10.1038/s41591-023-02726-5.
MLA (9th ed.) CitationLE, Budde, et al. "Mosunetuzumab with Polatuzumab Vedotin in Relapsed or Refractory Aggressive Large B Cell Lymphoma: A Phase 1b/2 Trial." Nature Medicine, vol. 30, no. 1, 2024, p. 229, https://doi.org/10.1038/s41591-023-02726-5.
Warning: These citations may not always be 100% accurate.
